User profiles for Barry L. Shulkin
 | barry shulkinadjunct professor or radiology; university of tennessee school of medicine Verified email at stjude.org Cited by 12561 |
[HTML][HTML] Malignant pheochromocytoma: current status and initiatives for future progress
…, HPH Neumann, K Pacak, BL Shulkin… - Endocrine-related …, 2004 - erc.bioscientifica.com
Pheochromocytomas are rare catecholamine-producing neuroendocrine tumors that are
usually benign, but which may also present as or develop into a malignancy. Predicting such …
usually benign, but which may also present as or develop into a malignancy. Predicting such …
Guidelines for imaging and staging of neuroblastic tumors: consensus report from the International Neuroblastoma Risk Group Project
…, K Kanegawa, F Giammarile, M Schmidt, BL Shulkin… - Radiology, 2011 - pubs.rsna.org
Neuroblastoma is an enigmatic disease entity; some tumors disappear spontaneously
without any therapy, while others progress with a fatal outcome despite the implementation of …
without any therapy, while others progress with a fatal outcome despite the implementation of …
Pheochromocytomas: Imaging with 2-[Fluorine-18]fluoro-2-deoxy-d-glucose PET1
BL Shulkin, NW Thompson, B Shapiro, IR Francis… - Radiology, 1999 - pubs.rsna.org
PURPOSE: To assess the sensitivity of positron emission tomography (PET) with 2-[fluorine-18]fluoro-2-deoxy-d-glucose
(FDG) in pheochromocytomas and, secondarily, to compare …
(FDG) in pheochromocytomas and, secondarily, to compare …
Irinotecan–temozolomide with temsirolimus or dinutuximab in children with refractory or relapsed neuroblastoma (COG ANBL1221): an open-label, randomised …
…, C Van Ryn, LY Alice, WB London, BL Shulkin… - The lancet …, 2017 - thelancet.com
Background Outcomes for children with relapsed and refractory neuroblastoma are dismal.
The combination of irinotecan and temozolomide has activity in these patients, and its …
The combination of irinotecan and temozolomide has activity in these patients, and its …
Semiquantitative mIBG scoring as a prognostic indicator in patients with stage 4 neuroblastoma: a report from the Children's oncology group
GA Yanik, MT Parisi, BL Shulkin… - Journal of nuclear …, 2013 - Soc Nuclear Med
Radiolabeled metaiodobenzylguanidine (mIBG) is a highly sensitive and specific marker for
detecting neuroblastoma. A semiquantitative mIBG score (Curie score [CS]) was assessed …
detecting neuroblastoma. A semiquantitative mIBG score (Curie score [CS]) was assessed …
Long-term follow-up of a phase III study of ch14. 18 (dinutuximab)+ cytokine immunotherapy in children with high-risk neuroblastoma: COG study ANBL0032
Purpose: Previously our randomized phase III trial demonstrated that immunotherapy including
dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children …
dinutuximab, a chimeric anti-GD2 mAb, GM-CSF, and IL2 improved survival for children …
123I-MIBG scintigraphy and 18F-FDG PET in neuroblastoma
SE Sharp, BL Shulkin, MJ Gelfand… - Journal of Nuclear …, 2009 - Soc Nuclear Med
The purpose of this study was to compare the diagnostic utility of 123 I-metaiodobenzylguanidine
( 123 I-MIBG) scintigraphy and 18 F-FDG PET in neuroblastoma. Methods: A total of …
( 123 I-MIBG) scintigraphy and 18 F-FDG PET in neuroblastoma. Methods: A total of …
Irinotecan, temozolomide, and dinutuximab with GM-CSF in children with refractory or relapsed neuroblastoma: a report from the Children's Oncology Group
…, FF Zhang, WB London, BL Shulkin… - Journal of Clinical …, 2020 - ascopubs.org
PURPOSE The combination of irinotecan, temozolomide, dintuximab, and granulocyte-macrophage
colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with …
colony-stimulating factor (I/T/DIN/GM-CSF) demonstrated activity in patients with …
Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy.
BL Shulkin, RJ Hutchinson, VP Castle, GA Yanik… - Radiology, 1996 - pubs.rsna.org
PURPOSE: To assess the uptake in neuroblastoma of 2-[fluorine-18] -fluoro-2-deoxy-D-glucose
(FDG) versus metaiodobenzylguanidine (MIBG). MATERIALS AND METHODS: …
(FDG) versus metaiodobenzylguanidine (MIBG). MATERIALS AND METHODS: …
[HTML][HTML] Phase I trial of a novel anti-GD2 monoclonal antibody, Hu14. 18K322A, designed to decrease toxicity in children with refractory or recurrent neuroblastoma
F Navid, PM Sondel, R Barfield, BL Shulkin… - Journal of clinical …, 2014 - ncbi.nlm.nih.gov
Purpose The addition of immunotherapy, including a combination of anti-GD2 monoclonal
antibody (mAb), ch14. 18, and cytokines, improves outcome for patients with high-risk …
antibody (mAb), ch14. 18, and cytokines, improves outcome for patients with high-risk …